Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2006

View Archived Issues

Novartis rounds up second quarter highlights

Cytoplasmic MKK7 identified as a novel target for the development of neuroprotective agents

HT-0712, a novel PDE4 inhibitor, enhances memory formation in aged mice

DX-88, a selective human plasma kallikrein inhibitor, protects mice brains from reperfusion injury

Ipsen and Tercica establish worldwide strategic collaboration in endocrinology

NOV-002 with carboplatin studied for platinum-resistant ovarian cancer

Cortex continues work to lift clinical hold on CX-717

Positive preliminary findings for inhaled TPI-ASM-8 in asthma

Novavax reports positive preclinical results for influenza vaccines

Dz13 targets c-Jun suppressing vascular permeability and inflammation in murine models

Bone and lung metastasis reduced in animals treated with TbetaRI inhibitor

First subjects complete phase IIb obesity study of AOD-9604

IT-101 begins phase I study in inoperable and metastatic solid tumors

SPA for OncoVAX phase III study in stage II colon carcinoma

Bayer to license BAY-76-7171

Gilead exercises option to acquire Corus Pharma

Organon in partnership to better predict drug toxicity

Somaxon updates Silenor program status

GSK report preclinical data on SB-742457 at ICAD

Recent patents describe new possible treatment options for endocrine-related disorders

Recent patents disclose new agents for depression, psychosis, sleep disorders, etc.

Novel therapeutic agents for immunological disorders disclosed in recent patents

Predix Pharmaceuticals updates progress with their AD clinical candidate PRX-03140

European Xeloda filing for gastric cancer accepted for review

Indian approval for nimotuzumab in head and neck cancer

Pharming seeks European approval for rhC1INH in acute HAE

Fast track designation for Nexavar in advanced melanoma

Novel GSK-3beta inhibitors derived from marine microorganisms reported at ICAD

New Abeta42 modulator identified by Shionogi

ProteoTech's lead compound shows preclinical efficacy in in vivo models of AD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026